The Consortium for TCR-mediated Regulation and Oncogenesis in Lymphomas of T cells (CONTROL-T) invites you to take part in the “International Symposium on T cells and T-cell lymphomas” on September 20-21, 2019, in Essen (Germany). This summit will bring together leading experts from the fields of pathology, genomics, imaging, modeling, cell signaling, cellular immunology, medical oncology, and experimental cell therapy dealing with normal T-cell biology and T-cell lymphomas.
For further information please see: CONTROL-T CONFERENCE 2019
or:Postet on August 20, 2019
We seek for an above-average dedicated person with documented postdoctoral experience enabling her/him to lead a project group. The employment ideally starts in July ’19 and initially runs until May 2022 (TV-L E13; 6 months probation), but candidates with a genuine long-term interest to pursue an academic career towards ‘Habilitation’ are desired for an envisioned prolongation. The host laboratory is affiliated with the local CECAD and the CMMC (PI Dr. M. Herling) and offers a versatile profile in competitive projects.Postet on July 19, 2019
Although T-cell prolymphocytic leukemia had already been recognized being distinct from CLL in 1976, until today it has been managed according to criteria for CLL as described by the international workshop on CLL (IWCLL). The T-PLL International Study group (TPLL-ISG) has now set up a first consensus paper defining guidelines for the diagnosis, treatment and response evaluation of T-PLL. These guidelines will provide a basis for clinical decision making and will help to compare results from clinical trials in T-PLL.Postet on July 15, 2019
The project, “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia“, was granted funding within the European ERA-net TRANSCAN 2 initiative (Horizon 2020).
The project is a cooperation of five European research groups from Austria, France and Germany, coordinated by Dr. Marco Herling (University Hospital of Cologne). It focuses on the development of new tools to predict individual in vitro drug sensitivities and synergies in the rare entity of T-cell prolymphocytic leukemia and implementation of these into the clinics.
Overall, the project is funded with 1.5 million euros.
For more details visit:
Postet on July 5, 2019